Barreto Monique Antunes de Souza Chelminski, Ledesma Aleluia Lima Losno, de Oliveira Carlos Augusto Costa Pires, Bahmad Fayez
Postgraduate Speech and Hearing, Universidade Federal de Santa Maria (UFSM), Santa Maria, RS, Brazil; Educational Psychology, Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, RJ, Brazil; Audiology and Neurotology, Universidade Federal de Pernambuco (UFPE), Recife, PE, Brazil; Universidade de Brasília (UnB), Brasília, DF, Brazil.
Universidade de Brasília (UnB), Brasília, DF, Brazil.
Braz J Otorhinolaryngol. 2016 May-Jun;82(3):353-64. doi: 10.1016/j.bjorl.2015.06.007. Epub 2015 Nov 6.
Sudden deafness is characterized by an abrupt hearing loss of at least 30dB in three sequential frequencies in the standard pure tone audiogram over three days or less. Treatment is based on its etiology, and oral corticosteroids are widely used. Intratympanic corticosteroids are included as primary or secondary treatment when there is no improvement with the use of oral corticosteroids.
To determine the effectiveness of therapy with intratympanic steroids in sudden deafness.
A systematic review was performed of publications on the topic in the databases of PubMed/MEDLINE, with the keywords: sudden deafness, sudden hearing loss, and corticosteroids.
Thirty scientific studies were analyzed. As to the objectives of the study analyzed, 76.7% sought to evaluate the use of intratympanic therapy salvage after failure to conventional treatment, and intratympanic therapy was used as the primary treatment 23.3% of the studies.
Intratympanic corticosteroid therapy is prescribed primarily when there is failure of conventional therapy and when it is limited to use systemic corticosteroids, such as the diabetic patient.
突发性聋的特征是在标准纯音听力图中,连续三天或更短时间内,三个连续频率的听力突然下降至少30dB。治疗基于其病因,口服糖皮质激素被广泛使用。当使用口服糖皮质激素没有改善时,鼓室内注射糖皮质激素作为主要或次要治疗方法。
确定鼓室内注射糖皮质激素治疗突发性聋的有效性。
在PubMed/MEDLINE数据库中对关于该主题的出版物进行系统综述,关键词为:突发性聋、突发性听力损失和糖皮质激素。
分析了30项科学研究。关于所分析研究的目的,76.7%试图评估在传统治疗失败后鼓室内治疗的挽救作用,23.3%的研究将鼓室内治疗用作主要治疗方法。
鼓室内糖皮质激素治疗主要在传统治疗失败以及仅限于使用全身性糖皮质激素(如糖尿病患者)时使用。